Global Information
회사소개 | 문의

제약 및 바이오테크놀러지 기업의 디스커버리 단계 제휴 조건과 계약 동향

Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2012- 2018

리서치사 Current Partnering, a division of Wildwood Ventures Limited
발행일 2018년 10월 상품 코드 121841
페이지 정보 영문 1000+ Pages
가격
US $ 2,995 ₩ 3,382,200 PDF by E-mail (Single User License)
US $ 4,495 ₩ 5,076,200 PDF by E-mail (Multi user license - 2 to 5 Users)
US $ 8,995 ₩ 10,158,000 PDF by E-mail (Multi User Site License - 6+ Users)
US $ 14,995 ₩ 16,933,800 PDF by E-mail (Global license)


제약 및 바이오테크놀러지 기업의 디스커버리 단계 제휴 조건과 계약 동향 Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2012- 2018
발행일 : 2018년 10월 페이지 정보 : 영문 1000+ Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

세계 주요 헬스케어 기업의 디스커버리 단계에서의 제휴 계약과 합의 내용에 대해 조사 분석하고, 디스커버리 단계에서 제휴하는 이유, 계약 전략과 구조, 지불 전략, 계약 활동, 지불 조건, 주요 계약, 관련 기업 개요, 제휴 계약 디렉토리 등의 정보를 전해드립니다.

주요 요약

제1장 서론

제2장 기업이 디스커버리 단계에서 제휴하는 이유

  • 서론
  • 디스커버리 단계에서 제휴의 역할
  • 디스커버리, 전임상 및 임상 단계에서의 계약 차이
  • 디스커버리 단계에서 제휴 계약을 체결하는 이유
  • 디스커버리 단계에서의 제휴 계약 전망

제3장 디스커버리 단계에서의 계약 전략과 구조

  • 서론
  • 어느 단계에서 기업은 제휴하는가?
  • 초기 및 후기 단계에서의 제휴 - 위험과 비용 비교
  • 기업은 디스커버리, 전임상 및 임상 단계에서의 제휴에 무엇을 소비하는가?
  • 단순 vs. 다요소 제휴 계약
  • 단순 라이선싱 계약 구조
  • 다요소 전임상 단계에서의 제휴 계약

제4장 디스커버리 단계에서의 제휴 지불 전략

  • 서론
  • 디스커버리 단계에서의 지불 전략
  • 지불 옵션

제5장 디스커버리 단계에서의 계약 형성 동향

  • 서론
  • 오랜 세월에 걸친 디스커버리 단계에서의 제휴
  • 대형 제약 기업의 디스커버리 단계에서의 계약 활동
  • 대형 바이오테크놀러지 기업의 디스커버리 단계에서의 계약 활동
  • 디스커버리 단계에서의 제휴 : 계약 종류별
  • 디스커버리 단계에서의 제휴 : 질병 종류별
  • 제휴 : 디스커버리 단계에서의 기술 종류별

제6장 디스커버리 단계에서의 제휴에 대한 평균적인 지불 조건

  • 서론
  • 디스커버리 단계에서의 지불 조건 지침
  • 디스커버리 단계에서의 지불 - 계약 데이터 분석
  • 지불 조건 분석

제7장 주요 디스커버리 단계에서의 계약

  • 서론
  • 주요 디스커버리 단계에서의 계약 : 금액별

제8장 대형 제약 기업 및 대형 바이오테크놀러지 기업의 디스커버리 단계에서의 제휴 계약

  • 서론
  • 대형 제약 기업 및 대형 바이오테크놀러지 기업의 디스커버리 단계에서의 제휴 계약을 이용하는 방법
  • 대형 제약 기업의 디스커버리 단계에서의 제휴 기업 개요
  • 대형 바이오테크놀러지 기업의 디스커버리 단계에서의 제휴 기업 개요

제9장 디스커버리 단계에서의 제휴 계약 디렉토리

  • 서론
  • 기업 A∼Z
  • 계약 종류별
  • 개발 단계별
  • 치료 영역별

제10장 디스커버리 단계에서의 계약 형성 디렉토리

  • 서론
  • 계약 : 디스커버리 단계별

부록

도표

KSM 13.05.14

The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018 report provides comprehensive understanding and unprecedented access to the discovery stage partnering agreements entered into by the worlds leading biopharma companies

The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018 report.

The report provides a detailed understanding and analysis of how, why and on what terms companies enter discovery stage partnering deals. These deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors product or technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest discovery agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all discovery stage partnering deals announced since 2012 including financial terms where available including over 3,000 links to online deal records of actual discovery partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of discovery stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner discovery stage compounds/products.

Chapter 3 provides an overview of discovery stage deals strategy and deal structure including numerous case studies. Chapter 4 provides an overview of the various payment strategies used in discovery stage deals.

Chapter 5 provides a review of discovery stage deal making since 2012. Deals activity is reviewed by year, therapeutic area, technology type, as well as most active dealmakers.

Chapter 6 provides a detailed analysis of discovery stage payment terms including headline, upfront, milestone and royalty rates.

Chapter 7 provides a review of the leading discovery stage deal by headline value. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 8 provides a comprehensive listing of the top 50 most active discovery stage dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 9 provides a comprehensive and detailed review of discovery stage partnering deals signed and announced since 2012, where a contract document is available in the public domain.

Chapter 10 provides a comprehensive directory of discovery stage partnering deals since 2012.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

The report also includes numerous tables and figures that illustrate the trends and activities in discovery stage partnering and deal making since 2012.

In addition, a comprehensive appendix of all discovery deals since 2012 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of discovery stage products and compounds.

Key benefits

Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018 provide the reader with the following key benefits:

  • In-depth understanding of discovery stage deal trends since 2012
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of discovery stage agreements with numerous real life case studies
  • Insight into the terms included in a discovery stage agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

  • Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018 is intended to provide the reader with an in-depth understanding and access to discovery stage deal trends and structure of deals entered into by leading companies worldwide.

Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018 include:

  • Trends in discovery stage dealmaking in the biopharma industry since 2012
  • Analysis of discovery stage deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life discovery stage deals
  • Access to over 3,000 discovery stage deals
  • The leading discovery stage deals by value since 2012
  • Most active discovery stage dealmakers since 2012
  • The leading discovery stage partnering 2012

In Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal type
  • Specific therapy target
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018 report provides comprehensive access to available deals and contract documents for over 3,000 discovery stage deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018 report provides the reader with the following key benefits:

  • In-depth understanding of discovery stage deal trends since 2012
  • Access to headline, upfront, milestone and royalty data
  • Comprehensive access to over 3,000 discovery stage deals together with contract documents if available
  • Detailed access to actual discovery stage deals entered into by the leading fifty big pharma and big biotech companies along with other biopharma companies
  • Analysis of the structure of discovery stage agreements with numerous real life case studies
  • Identify leading discovery stage deals by value since 2012
  • Identify the most active discovery stage dealmakers since 2012
  • Full listing of discovery stage deals by company A-Z, phase of development, deal type, therapy and technology focus
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Why do companies partner at discovery stage?

  • 2.1. Introduction
  • 2.2. The role of discovery stage partnering
    • 2.2.1. In-licensing at discovery stage
    • 2.2.2. Out-licensing at discovery stage
  • 2.3. Difference between discovery, preclinical and clinical stage deals
  • 2.4. Reasons for entering into discovery stage partnering deals
    • 2.4.1. Licensors reasons for entering discovery stage deals
    • 2.4.2. Licensees reasons for entering discovery stage deals
  • 2.5. The future of discovery stage partnering deals

Chapter 3 - Discovery stage deal strategies and structure

  • 3.1. Introduction
  • 3.2. At what stage do companies partner?
    • 3.2.1. Partnering early in pharmaceutical/biotech
    • 3.2.1.1. Discovery and preclinical stage partnering case studies
    • 3.2.1.1.a. Case study: LEO Pharma - 4SC
    • 3.2.1.1.b. Case study: Heptares Therapeutics - Cubist
    • 3.2.1.1.c. Case study: Incyte - Agenus Bio
    • 3.2.1.1.d. Case study: Janssen Pharmaceutical - Evotec
    • 3.2.2. Partnering later in pharmaceutical/biotech
    • 3.2.2.1. Clinical stage partnering case studies
    • 3.2.2.1.a. Case study: Servier - GeNeuro
    • 3.2.2.1.b. Case study: Teva - Xenon Pharmaceuticals
    • 3.2.2.1.c. Case study: AstraZeneca - Ardelyx
    • 3.2.2.1.d. Case study: Baxter - Onconova Therapeutics
  • 3.3. Early and later stage partnering - a risk/cost comparison
  • 3.4. What do companies spend on discovery, preclinical and clinical stage partnering?
  • 3.5. Pure versus multi-component partnering deals
  • 3.6. Pure licensing agreement structure
    • 3.6.1. Example pure licensing agreements
    • 3.6.1.a. Case study : Pfizer - Spark Therapeutics
    • 3.6.1.b. Case study : Contrafect - Trellis Bioscience
  • 3.7. Multicomponent discovery stage partnering agreements
    • 3.7.1.a. Example multicomponent early stage clauses
    • 3.7.1.a. Case study: Tracon - Boehringer Ingelheim - Macrogenics
    • 3.7.1.b. Case study: Fibrocell Science - Intrexon

Chapter 4 - Discovery stage partnering payment strategies

  • 4.1. Introduction
  • 4.2. Discovery stage payment strategies
  • 4.3. Payment options
    • 4.3.1. Headline values
    • 4.3.2. Upfront payments
    • 4.3.2.1. Conditionality of upfront payments
    • 4.3.3. Loans
    • 4.3.4. Convertible loans
    • 4.3.5. Equity
    • 4.3.6. R&D funding
    • 4.3.7. Licensing fees
    • 4.3.8. Milestone payments
    • 4.3.9. Royalty payments
    • 4.3.9.1. Issues affecting royalty rates
    • 4.3.9.2. Royalties on combination products
    • 4.3.9.2.a. Case study: Scripps Research Institute-Cyanotech
    • 4.3.9.3. Guaranteed minimum/maximum annual payments
    • 4.3.9.4. Royalty stacking
    • 4.3.9.5. Royalties and supply/purchase contracts
    • 4.3.10. Quids
    • 4.3.11. Option payments

Chapter 5 - Trends in discovery stage deal making

  • 5.1. Introduction
  • 5.2. Discovery stage partnering over the years
    • 5.2.1. Attributes of discovery deals
  • 5.3. Discovery stage partnering by deal type
  • 5.4. Discovery stage partnering by disease type
  • 5.5. Partnering by discovery stage technology type
  • 5.6. Discovery stage partnering by most active company since 2012

Chapter 6 - Payment terms for discovery stage partnering

  • 6.1. Introduction
  • 6.2. Guidelines for discovery stage payment terms
    • 6.2.1. Upfront payments
    • 6.2.2. Milestone payments
    • 6.2.3. Royalty payments
  • 6.3. Discovery stage payment terms - deal data analysis
    • 6.3.1. Public data
    • 6.3.2. Survey data
  • 6.4. Payment terms analysis
    • 6.4.1. Discovery stage headline values
    • 6.4.2. Discovery stage deal upfront payments
    • 6.4.3. Discovery stage deal milestone payments
    • 6.4.4. Discovery stage royalty rates

Chapter 7 - Leading discovery stage deals

  • 7.1. Introduction
  • 7.2. Top discovery stage deals by value

Chapter 8 - Top 50 most active discovery stage dealmakers

  • 8.1. Introduction
  • 8.2. Top 50 most active discovery stage dealmakers

Chapter 9 - Discovery stage partnering contracts directory

  • 9.1. Introduction
  • 9.2. Discovery stage deals with contracts 2012 to 2018

Chapter 10 - Discovery stage deal making by development stage

  • 10.1. Introduction
  • 10.2. Deals by discovery stage

Appendices

  • Appendix 1 - Discovery stage dealmaking by companies A-Z
  • Appendix 2 - Discovery stage dealmaking by industry sector
  • Appendix 3 - Discovery stage dealmaking by stage of development
  • Appendix 4 - Discovery stage dealmaking by therapy area
  • Appendix 5 - Discovery stage dealmaking by technology type

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

TABLE OF FIGURES:

  • Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking
  • Figure 2: Agreements signed by phase of development (2012-2018), % of all deals where stage disclosed
  • Figure 3: Components of the pure licensing deal structure
  • Figure 4: Payment options for discovery stage partnering deals
  • Figure 5: Issues affecting royalty rates
  • Figure 6: Discovery stage partnering frequency since 2012
  • Figure 7: Discovery stage partnering by deal type since 2012
  • Figure 8: Discovery stage partnering by disease type since 2012
  • Figure 9: Discovery stage partnering by technology type since 2012
  • Figure 10: Top 50 most active discovery stage dealmakers since 2012
  • Figure 11: Review of median upfront payments for discovery stage deals
  • Figure 12: Review of median milestone payments for discovery stage deals
  • Figure 13: Review of median royalty payments for discovery stage deals
  • Figure 14: Discovery stage deals with a headline value
  • Figure 15: Discovery stage deals with an upfront value
  • Figure 16: Discovery stage deals with a milestone value
  • Figure 17: Discovery stage deals with a royalty rate value
  • Figure 18: Top discovery stage deals that exceeds $1 billion in deal value since 2012
  • Figure 19: Most active discovery stage dealmakers since 2012
Back to Top
전화 문의
이용안내
 
BCC Research